INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number

10/519,162

Filling Date
December 23, 2004

First Named Inventor
Art Unit
Not Yet Assigned
Not Yet Assigned

Attorney Docket Number

09707.0001

Examiner Initials	Cite No.1	Document Number Issue or	Name of Patentee or	Pages, Columns, Lines, Where	
		Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US-6,566,394	05-20-2003	Takeuchi et al.	
		US-2004/0259877	12-23-2004	Muto et al.	
		US-5,804,374	09-08-1998	Baltimore et al.	
-		US-6,150,090	11-21-2000	Baltimore et al.	
	_	US-6,410,516	06-25-2002	Baltimore et al.	

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

Sheet

	FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶	
		WO 00/26197	05-11-2000	GU et al.			
		WO 99/65449	12-23-1999	CALLAHAN et al.			
<u> </u>		WO 00/30587	06-02-2000	HIRSCH et al.		Abstract	
		WO 01/02548	01-11-2001	FORD et al.			
		WO 00/61167	10-19-2000	MUNDY			
		WO 01/47543	07-05-2001	FOXWELL et al.			
		JP 10-045738	02-17-1998	TAKEUCHI et al.		English abstract and English translation	
		JP 09-157266	06-17-1997	TAKEUCHI et al.		English abstract and English translation	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO

Application Number 10/519,162

INFORMATION DISCLOSURE

Filing Date Complete if an application Number December

Complete if Known			
Application Number	10/519,162		
Filing Date	December 23, 2004		
First Named Inventor	Kazuo UMEZAWA		
Art Unit	Not Yet Assigned		
Examiner Name	Not Yet Assigned		
Attorney Docket Number	09707.0001		

(Use as many sheets as necessary)

STATEMENT BY APPLICANT

Sheet 2 of 3 Attorney Dock

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
	<u>-</u>	SUMITOMO et al., "INDUCTION OF APOPTOSIS OF CYTOKINE-PRODUCING BLADDER CANCER CELLS BY ADENOVIRUS-MEDIATED IKBO OVEREXPRESSION", Human Gene Therapy, 10, pp. 37-47, (1999).	
		ROMIEU-MOUREZ et al., "ROLES OF IKK KINASES AND PROTEIN KINASE CK2 IN ACTIVATION OF NUCLEAR FACTOR-KB IN BREAST CANCER", Cancer Research, 61, pp. 3810-3818, (2001).	
		YANG et al., "CONSTITUTIVE IKB KINASE ACTIVITY CORRELATES WITH NUCLEAR FACTOR -KB ACTIVATION IN HUMAN MELANOMA CELLS", Cancer Research, 61, 4901-4909, (2001).	
		NARA et al., "ELUCIDATION OF CANCER CACHEXIA-INDUCING FACTORFOCUSING ON CYTOKINES", Growth Factor Division, National Cancer Center Research Institute, Vol. 54, No. 10, pp. 2502-2507, (1999).	
		GHOSH et al., "NF-kB AND REL PROTEINS: EVOLUTIONARILY CONSERVED MEDIATORS OF IMMUNE RESPONSES", Annu. Rev. Immunol., 16, pp. 225-260, (1998).	
		MATSUMOTO et al., "SYNTHESIS OF NF-kB ACTIVATION INHIBITORS DERIVED FROM EPOXYQUINOMICIN C", Bioorganic & Medicinal Chemistry Letters, 10, pp. 865-869, (2000).	
		ALBERT S. BALDWIN, "CONTROL OF ONCOGENESIS AND CANCER THERAPY RESISTANCE BY THE TRANSCRIPTION FACTOR NF-kB", The Journal of Clinical Investigation, Vol. 107, No. 3, pp. 241-246, (2001).	
		ERKEL et al., "INHIBITION OF NF-kB ACTIVATION BY PANEPOXYDONE", Biochemical and Biophysical Research Communications, 226, pp. 214-221, (1996).	
		GEHRT et al., "CYCLOEPOXYDON, 1-HYDROXY-2-HYDROXYMETHYL-3-PENT-1-ENYLBENZENE AND 1-HYDROXY-2-HYDROXYMETHYL-3-PENT-1,3-DIENYLBENZENE, NEW INHIBITORS OF EUKARYOTIC SIGNAL TRANSDUCTION", The Journal of Antibiotics, Vol. 51, No. 5, pp. 455-463, (1998).	
		LIN et al., "INHIBITION OF NUCLEAR TRANSLOCATION OF TRANSCRIPTION FACTOR NF-kB BY A SYNTHETIC PEPTIDE CONTAINING A CELL MEMBRANE-PERMEABLE MOTIF AND NUCLEAR LOCALIZATION SEQUENCE", The Journal of Biological Chemistry, Vol. 270, No. 24, pp. 14255-14258, (1995).	
		WIPF et al., "SYNTHESIS OF ()-LL-C10037α AND RELATED MANUMYCIN-TYPE EXPOXYQUINOLS", Synthesis, pp. 1549-1561, (1995).	
		ARIGA et al., "INHIBITION OF TUMOR NECROSIS FACTOR-α-INDUCED NUCLEAR TRANSLOCATION AND ACTIVATION OF NF-κB BY DEHYDROXYMETHYLEPOXYQUINOMICIN", The Journal of Biological Chemistry, Vol. 227, No. 27, pp. 24625-24630, (2002).	
		MASFERRER et al., "ANTIANGIOGENIC AND ANTITUMOR ACTIVITIES OF CYCLOOXYGENASE-2 INHIBITORS", Cancer Research, 60, pp. 1306-1311, (2000).	*
		TANAKA et al., "A NOVEL MONOCLONAL ANTIBODY AGAINST MURINE IL-2 RECEPTOR β-CHAIN Characterization of Receptor Expression in Normal Lymphoid Cells and El-4 Cells", The Journal of Immunology, Vol. 147, pp. 2222-2228, (1991).	
		UMEZWA et al., "ANTICANCER AGENT-RESISTANT FACTORS", Surgery Frontier, Vol. 9, No. 2, pp. 88-91, (2002).	
		ASEA et al., "NOVEL SIGNAL TRANSDUCTION PATHWAY UTILIZED BY EXTRACELLULAR HSP70 Role of Toll-LIKE RECEPTOR (TLR) 2 AND TLR4", The Journal of Biological Chemistry, Vol. 277, No. 17, pp. 15028-15034, (2002).	
		YAN et al., "BENZO[a]PYRENE INDUCES THE TRANSCRIPTION OF CYCLOOXYGENASE-2 IN VASCULAR SMOOTH MUSCLE CELLS", The Journal of Biological Chemistry, Vol. 275, No. 7, pp. 4949-4955, (2000).	
		HISHIKAWA et al., "TOWARDS MOLECULE UNDERSTANDING OF DRUG MECHANISM OF ACTION AND BIOLOGICAL FUNCTIONS", Folia Pharmacol. Jpn. Vol. 118, pp. 197-202, (2001).	
		SEN et al., "MULTIPLE NUCLEAR FACTORS INTERACT WITH THE IMMUNOGLOBULIN ENHANCER SEQUENCES", Cell, Vol. 46, pp. 705-716, (1986).	
		ALBERT S. BALDWIN, JR., "THE NF-kB AND I-kB PROTEINS: New Discoveries and Insights", Annu. Rev. Immunol., 14, pp. 649-683, (1996).	
		BAEUERLE et al., "NF-kB TEN YEARS AFTER", Cell, Vol. 87, pp. 13-20, (1996).	
		BAEUERLE et al., "FUNCTION AND ACTIVATION OF NF-kB IN THE IMMUNE SYSTEM", Annu. Rev. Immunol., 12, pp. 141-179, (1994).	

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number

10/519,162

Filing Date

December 23, 2004

First Named Inventor

Art Unit

Not Yet Assigned

Examiner Name

Not Yet Assigned

Attorney Docket Number

09707.0001

3

Sheet

NON PATENT LITERATURE DOCUMENTS			
TAYLOR et al., "THE SYNTHESIS OF ALISAMYCIN, NISAMYCIN, LL-C10037α AND NOVEL EPOXYQUINOL AND EPOXYQUINONE ANALOGUES OF MANUMYCIN A", Synthesis, pp. 775-790, (1998).			
KIKUCHI et al., "SUPPRESSION OF HORMONE-REFRACTORY PROSTATE CANCER BY A NOVEL NUCLEAR FACTOR KB INHIBITOR IN NUDE MICE", Cancer Research, 63, pp. 107-110, (2003).			
UMEZAWA et al., "MOLECULAR DESIGN AND BIOLOGICAL ACTIVITIES OF NF-kB INHIBITORS", Molecules and Cells, Vol. 14, No. 2, pp. 163-167, (2002).			
CHAICHAROENPONG et al., "SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP OF DEHYDROXYMETHYLEPOXYQUINOMICIN ANALOGUES AS INHIBITORS OF NF-kB FUNCTIONS", Bioorganic & Medicinal Chemistry, 10, pp. 3933-3939, (2002).			
UMEZAWA et al., "NATURALLY OCCURRING AND SYNTHETIC INHIBITORS OF NF-kB FUNCTIONS", Anti-Cancer Drug Design, Vol. 15, No. 4, pp. 239-244, (2000).			
MATSUMOTO et al., "INHIBITION OF RAT EMBRYO HISTIDINE DECARBOXYLASE BY EPOXYQUINOMICINS", The Journal of Antibiotics, Vol. 53, No. 6, pp. 637-639, (2000).			
KASAHARA et al., "ANTI-TNFα ANTIBODY 1", Vol. 36, No. 12, pp. 1-7, (2002).			
MURAKAMI et al., "EFFECTS OF TNF-a AND CELLULAR FUNCTIONS", The Lipid, Vol. 9, No. 5, pp. 1-10, (1998).			

Examiner	/Kyle Purdy/	Date	00/22/2000
Signature	, sylv i acay,	Considered	00/22/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.